Antiglomerular basement membrane (Goodpasture) disease

Pusey CD. Anti-glomerular basement membrane disease. Kidney Int. 2003 Jul 7;64(7):1535-50. Abstract

Shah MK, Hugghins SY. Characteristics and outcomes of patients with Goodpasture's syndrome. South Med J. 2002 Dec;95(12):1411-8. Abstract

Kluth DC, Rees AJ. Anti-glomerular basement membrane disease. J Am Soc Nephrol. 1999 Nov;10(11):2446-53.Full text  Abstract

Connelly-Smith L, Alquist CR, Aqui NA, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the Writing Committee of the American Society for Apheresis: the ninth special issue. J Clin Apher. 2023 Apr;38(2):77-278. Abstract

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4s):S1-S276.Full text  Abstract

1. Pusey CD. Anti-glomerular basement membrane disease. Kidney Int. 2003 Jul 7;64(7):1535-50. Abstract

2. Sethi S, Lewin M, Lopez L, et al. Linear anti-glomerular basement membrane IgG but no glomerular disease: Goodpasture's syndrome restricted to the lung. Nephrol Dial Transplant. 2007 Apr;22(4):1233-3. Abstract

3. Shah MK, Hugghins SY. Characteristics and outcomes of patients with Goodpasture's syndrome. South Med J. 2002 Dec;95(12):1411-8. Abstract

4. Kluth DC, Rees AJ. Anti-glomerular basement membrane disease. J Am Soc Nephrol. 1999 Nov;10(11):2446-53.Full text  Abstract

5. Niles JL, Bottinger SP, Saurina GT, et al. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med. 1996 Feb 26;156(4):440-5. Abstract

6. Donaghy M, Rees AJ. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet. 1983 Dec 17;2(8364):1390-3. Abstract

7. Herody M, Duvic C, Noel LH, et al. Cigarette smoking and other inhaled toxins in anti-GBM disease. Contrib Nephrol. 2000;130:94-102. Abstract

8. Phelps RG, Rees AJ. The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity. Kidney Int. 1999 Nov;56(5):1638-54. Abstract

9. Lerner RA, Glassock RJ, Dixon FJ. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med. 1967 Dec 1;126(6):989-1004. Abstract

10. Ryan JJ, Reynolds J, Norgan VA, et al. Expression and characterization of the recombinant rat alpha 3(IV)NC1 and its use in induction of experimental autoimmune glomerulonephritis. Nephrol Dial Transplant. 2001 Feb;16(2):253-61.Full text  Abstract

11. Tipping PG, Holdsworth SR. T cells in crescentic glomerulonephritis. J Am Soc Nephrol. 2006 May;17(5):1253-63.Full text  Abstract

12. Wu J, Hicks J, Borillo J, et al. CD4(+) T cells specific to a glomerular basement membrane antigen mediate glomerulonephritis. J Clin Invest. 2002 Feb;109(4):517-24.Full text  Abstract

13. Cairns LS, Phelps RG, Bowie L, et al. The fine specificity and cytokine profile of T-helper cells responsive to the alpha3 chain of type IV collagen in Goodpasture's disease. J Am Soc Nephrol. 2003 Nov;14(11):2801-12.Full text  Abstract

14. Serisier DJ, Wong RC, Armstrong JG. Alveolar haemorrhage in anti-glomerular basement membrane disease without detectable antibodies by conventional assays. Thorax. 2006 Jul;61(7):636-9.Full text  Abstract

15. Bombassei GJ, Kaplan AA. The association between hydrocarbon exposure and anti-glomerular basement membrane antibody-mediated disease (Goodpasture's syndrome). Am J Ind Med. 1992;21(2):141-53. Abstract

16. Lauwerys R, Bernard A, Viau C, et al. Kidney disorders and hematotoxicity from organic solvent exposure. Scand J Work Environ Health. 1985;11 Suppl 1:83-90.Full text  Abstract

17. Anonide A, Rebora A. What lichen planus patients die of: a retrospective study. Int J Dermatol. 1989 Oct;28(8):524-6. Abstract

18. Boardman EA, Sohail S, Yadavilli R. Goodpasture's disease with late presentation of renal abnormality and anti-GBM autoantibody. BMJ Case Rep. 2017 Mar 17;2017. Abstract

19. Wilson CB, Smith RC. Goodpasture's syndrome associated with influenza A2 virus infection. Ann Intern Med. 1972 Jan;76(1):91-4.

20. Prendecki M, Clarke C, Cairns T, et al. Anti-glomerular basement membrane disease during the COVID-19 pandemic. Kidney Int. 2020 Sep;98(3):780-81.Full text

21. Phelps R, Winston JA, Wynn D, et al. Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Mult Scler. 2019 Aug;25(9):1273-88.Full text  Abstract

22. Clatworthy MR, Wallin EF, Jayne DR. Anti-glomerular basement membrane disease after alemtuzumab. N Engl J Med. 2008 Aug 14;359(7):768-9.Full text

23. Javaugue V, Watson MJ, Fervenza FC, et al. Atypical antiglomerular basement membrane nephritis following immune checkpoint inhibitor. Kidney Int Rep. 2022 Aug;7(8):1913-16.Full text

24. Al-Chalabi S, Wu HHL, Chinnadurai R, et al. Etanercept-induced anti-glomerular basement membrane disease. Case Rep Nephrol Dial. 2021 Sep-Dec;11(3):292-300.Full text  Abstract

25. Browne G, Brown PA, Tomson CR, et al. Retransplantation in alport post-transplant anti-GBM disease. Kidney Int. 2004 Feb;65(2):675-81.Full text  Abstract

26. Hudson BG, Kalluri R, Gunwar S, et al. The pathogenesis of Alport syndrome involves type IV collagen molecules containing the alpha 3(IV) chain: evidence from anti-GBM nephritis after renal transplantation. Kidney Int. 1992 Jul;42(1):179-87.Full text  Abstract

27. Connelly-Smith L, Alquist CR, Aqui NA, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the Writing Committee of the American Society for Apheresis: the ninth special issue. J Clin Apher. 2023 Apr;38(2):77-278. Abstract

28. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021 Oct;100(4s):S1-S276.Full text  Abstract

29. Swaak AJ, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis. 1986 May;45(5):359-66. Abstract

30. Reggiani F, L'Imperio V, Calatroni M, et al. Goodpasture syndrome and anti-glomerular basement membrane disease. Clin Exp Rheumatol. 2023 Apr;41(4):964-74.Full text  Abstract

31. van Daalen EE, Jennette JC, McAdoo SP, et al. Predicting outcome in patients with anti-GBM glomerulonephritis. Clin J Am Soc Nephrol. 2018 Jan 6;13(1):63-72.Full text  Abstract

32. O'Driscoll BR, Howard LS, Earis J, et al. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017 Jun;72(suppl 1):ii1-ii90.Full text  Abstract

33. Levy JB, Turner AN, Rees AJ, et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001 Jun 5;134(11):1033-42. Abstract

34. Kant S, Kronbichler A, Sharma P, et al. Advances in understanding of pathogenesis and treatment of immune-mediated kidney disease: a review. Am J Kidney Dis. 2022 Apr;79(4):582-600.Full text  Abstract

35. Hu W, Liu Z, Ji D, et al. Staphylococcal protein A immunoadsorption for Goodpasture's syndrome in four Chinese patients. J Nephrol. 2006 May-Jun;19(3):312-7. Abstract

36. Bygren P, Freiburghaus C, Lindholm T, et al. Goodpasture's syndrome treated with staphylococcal protein A immunoadsorption. Lancet. 1985 Dec 7;2(8467):1295-6. Abstract

37. Huart A, Josse AG, Chauveau D, et al. Outcomes of patients with Goodpasture syndrome: a nationwide cohort-based study from the French Society of Hemapheresis. J Autoimmun. 2016 Sep;73:24-9. Abstract